Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback